Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Would Lose Direct Access To User Fees Under House Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA would lose the ability to negotiate with user fee payors on use of the funds under legislation introduced by Rep. Hinchey (D-N.Y.). The bill also would place restrictions on advisory committee members with financial ties to the industry.

You may also be interested in...



Drug Safety Act Expands Withdrawal Authority; Final Decision Rests With Commissioner

The proposed FDA Safety Act would enable the Center for Postmarket Drug Evaluation & Research to call for a drug's withdrawal, with final authority retained by the FDA commissioner

Fraud Discovery Institute Asks Waxman To Address Lead In Herbalife Products

FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation

Fraud Discovery Institute Asks Waxman To Address Lead In Herbalife Products

FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation

Topics

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel